Back to School: How biopharma can reboot drug development. Access exclusive analysis here
Final data from a Phase II trial showed that 10 mg of AEGR-773 plus 10 mg of Zetia
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury